Contribution of Positron Emission Tomography in Biological Targeting by Conformational Radiotherapy and Intensity-modulated Radiotherapy of Ear, Nose and Throat Tumors
- To assess the value of pre-treatment PET in determining the target volume in patients
with head and neck cancer undergoing three-dimensional conformational radiotherapy and
- To evaluate variations in weekly fludeoxyglucose F 18 PET imaging during the first 5
weeks of treatment.
- To determine the relationship between changes in tumor metabolism during radiotherapy
and control tumor at 3 months and at 1 year post-treatment.
OUTLINE: This is a multicenter study.
Patients undergo fludeoxyglucose F18 PET (FDG-PET) in addition to conventional imaging at
baseline. Patients undergo standard three-dimensional conformational radiotherapy and
intensity-modulated radiation therapy 5 days a week for 5 weeks.
Some patients also undergo weekly FDG-PET during treatment.
Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Diagnostic
Difference between the target volume to be irradiated as measured by conventional imagining and PET
Eric Lartigau, MD, PhD
Centre Oscar Lambret
United States: Federal Government